Melanoma

Clinical results reported for heat shock protein-based immunotherapy

Published in Vaccine Weekly, May 14th, 2003

A presentation by Mojave Therapeutics, Inc., at The Future of Vaccines Conference in Semmering, Austria, included an update on the company's melanoma clinical trial and results from recent pre-clinical studies showing dramatically increased effectiveness of Javelin, Mojave's lead technology platform.

Mojave Therapeutics, Inc. is developing heat shock protein-based immunotherapies. Brian Barber, PhD, its chief scientific officer and senior vice-president, delivered a talk entitled "Delivering T-cell immunity with heat shock proteins."

In a previously reported study of 27 metastatic melanoma patients (AJCC Stages III and IV), formulations based on the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-05-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry